Paul Richardson, MD
Enriched profileClinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center; RJ Corman Professor of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Paul Richardson is Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center; RJ Corman Professor of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 2,062 publications with 132,822 citations (h-index 172); ClinicalTrials.gov lists 18 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Paul Richardson as a Highly Cited Researcher (Clinical Medicine, 2019-2024).
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Paul G. Richardson, MD, is Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute (Harvard Medical School affiliate). The public record shows 2,062 publications with 132,822 citations (h-index 172), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 24 companies, 1 NIH-funded awards (2005–2007).
- Most recent indexed publication: 2026 · European journal of haematology
- Top research focus: Multiple Myeloma Research and Treatments
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 83 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 886.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Sponsor: Prolexys Pharmaceuticals
Industry payments
Updated 27 Aug 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20256 payments$30,710openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20258 payments$16,848openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20256 payments$13,668openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
28.6%Thalidomide Analog28.6%Revlimid71%Pomalyst30%Part D≥42 patientsSensory organs
24.3%Other antiinfectives21%Chlorhexidine Gluconate100%Part D≥57 patientsCorticosteroid3.3%Dexamethasone100%Part D≥12 patientsDermatology
18.8%Azole Antifungal18.8%Clotrimazole100%Part D≥48 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2005–2007 per NIH RePORTER. The latest:
- defibrotide for the treatment of severe hepatic veno-cc*
Dana-Farber Cancer Inst
FY2007$366,742R01FD002548 - Defibrotide for the treatment of severe hepatic veno-cc*
Dana-Farber Cancer Institute
FY2005R01FD002548
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Expert opinion on biological therapy
Review2026 - Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events.
American journal of hematology
Guideline2025 - Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Expert opinion on emerging drugs
Review2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc2,847 citations2011
- 04A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma2,642 citations2003
- 05International uniform response criteria for multiple myeloma2,640 citations2006
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
dana-farber.org/find-a-doctor/paul-g-richardson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Other
myeloma.org/videos/ash-2016-multiple-myeloma-overview-dr-paul-richardson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myeloma.org ↗ - X / Twitter
x.com/DanaFarber/status/1978502379562483805
Mentions by others
where others cite or feature them- X / Twitter
Dana-Farber (official @DanaFarber X account) congratulating Paul Richardson, MD on the Joseph Michaeli Award
- X / Twitter
Lymphoma, Leukemia & Myeloma Congress (@llmcongress X account) announcing Richardson's keynote and Michaeli Award
- LinkedIn
Dana-Farber LinkedIn post referencing IMF naming Dr. Richardson for the Kyle Lifetime Achievement Award
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
- MD
Medical College of St. Bartholomew's Hospital, University of London (UK)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →managingmyeloma.com ↗
Editorial & leadership roles
journal and society appointments- Chair (2011-2021, then emeritus Chair to 2023)
Multiple Myeloma Committee, Alliance for Clinical Trials in Oncology
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globaloncologyacademy.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hms.harvard.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine201920202021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- Joseph Michaeli Award for Outstanding Contributions to Myeloma
Lymphoma Leukemia & Myeloma Congress
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - Joseph Michaeli Award for Outstanding Contributions to Myeloma
Lymphoma Leukemia & Myeloma Congress
2025 - James Griffin Team Science Award
Dana-Farber (2023), co-recipient as part of the Multiple Myeloma clinical research group, inaugural award
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Brigham and Women's Hospital
Boston, MA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hms.harvard.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →myelomacrowd.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Nikhil Munshi, MD
Dana-Farber Cancer Institute